| Stage | EMN | % of rev | CNMD | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $2.4B | 100.00% | $336M | 100.00% | EMN ×7.11 |
| Gross profit | $532M | 22.31% | $189M | 56.37% | CNMD +34.1pp |
| Operating income | $305M | 12.79% | $37M | 11.07% | EMN +1.7pp |
| Pre-tax income | $249M | 10.44% | $26M | 7.75% | EMN +2.7pp |
| Net income | $253M | 10.61% | $20M | 5.90% | EMN +4.7pp |
| Stage | EMN | CNMD | Gap · A − B |
|---|---|---|---|
| Revenue | $2.4B100.00% | $336M100.00% | EMN ×7.11 |
| Gross profit | 22.31%$532M | 56.37%$189M | CNMD +34.1pp |
| Operating income | 12.79%$305M | 11.07%$37M | EMN +1.7pp |
| Pre-tax income | 10.44%$249M | 7.75%$26M | EMN +2.7pp |
| Net income |
| 10.61%$253M |
| 5.90%$20M |
| EMN +4.7pp |
No shared counterparties.